Dr Paul Peter Tak of GlaxoSmithKline describes the possible, disadvantageous consequences of a no-deal Brexit.
Dr Paul Peter Tak of GlaxoSmithKline describes the possible, disadvantageous consequences of a no-deal Brexit.
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative
